Subtype
Malignant Colorectal Neoplasm
CI-CAN-00005874Explore in graph →
1,567 active trials21 approved drugs382 evidence items
- NCIt
- C4978
- OncoTree
- BOWEL
- DOID
- 9256
- Other
- 1 more code
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00005874Explore in graph →
Clinical trials
7,298 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (722)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07596290 | Yang et al. Anti-PD-1/CTLA-4 Dual Immunotherapy for LARC(RADICAL) | not yet recruiting | Phase 2 / Phase 3 | 342 | Beijing Friendship HospitalOTHER | 0 | Jun 17, 2026 | clinicaltrials |
| NCT03657641 | Regorafenib and Pembrolizumab in Treating Participants With Advanced or Metastatic Colorectal Cancer | active not recruiting | Phase 1 / Phase 2 | 73 | University of Southern CaliforniaOTHER | 1 | Jun 16, 2026 |
| clinicaltrials |
| NCT05038254 | Enhanced Outpatient Symptom Management to Reduce Acute Care Visits Due to Chemotherapy-Related Adverse Events | active not recruiting | N/A | 750 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT06642844 | Bevacizumab-based Chemotherapy Adapted to Bevacizumab Pharmacokinetics in 1st-line Treatment(PHARBEVACOL) | recruiting | Phase 3 | 244 | University Hospital, ToursOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT06843434 | A Study of Botensilimab and Balstilimab for Rectal Adenocarcinoma | recruiting | Phase 2 | 40 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT07337590 | Anastomotic Safety and Surveillance Using Real-time Enhanced Sensing Using xBar(ASSURE) | recruiting | N/A | 80 | Exero Medical Ltd.INDUSTRY | 1 | Jun 16, 2026 | clinicaltrials |
| NCT07649473 | QL1706 Combined With Standard Therapy for Conversion Therapy of Synchronous Liver Metastases From Colon Cancer: a Multicenter, Single-arm, Exploratory Study | not yet recruiting | Phase 2 | 30 | Fujian Medical UniversityOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT07650357 | A Study of CLSP 5282 in HLA-A*03:01 Positive Adult Patients With Solid Tumors (SENTINEL-101) | not yet recruiting | Phase 1 | 140 | Clasp Therapeutics, Inc.INDUSTRY | 1 | Jun 16, 2026 | clinicaltrials |
| NCT07650409 | A Dietary Intervention (Soy Soft Pretzels) for Reducing Chronic Inflammation in Obese Individuals | active not recruiting | N/A | 30 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT07651007 | Short-course RT Followed by NALIRIFOX Plus Pucotenlimab as Neoadjuvant Therapy for High-risk Locally Advanced Rectal Cancer With MSS/pMMR | not yet recruiting | Phase 2 | 29 | Wang XinOTHER | 0 | Jun 16, 2026 | clinicaltrials |
| NCT02945033 | Study on Aspirin Versus Placebo in Resected Colon Cancer With PI3K Mutation Stage III or II High Risk(ASPIK French) | active not recruiting | Phase 3 | 264 | University Hospital, RouenOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT05358249 | Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation(KontRASt-03) | active not recruiting | Phase 1 / Phase 2 | 74 | Novartis PharmaceuticalsINDUSTRY | 8 | Jun 15, 2026 | clinicaltrials |
| NCT05943210 | The Radiation Oncology-Biology Integration Network (ROBIN) Molecular Characterization Trial (MCT) of Standard Short Course Radiotherapy for Rectal Cancer(ROBIN) | recruiting | N/A | 25 | Weill Medical College of Cornell UniversityOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT06964438 | Postoperative Electrical Muscle Stimulation Two(POEMS2) | recruiting | N/A | 45 | University of NottinghamOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT07646639 | Different-Dose SCRT Plus CAPOX, PD-1 Blockade and IL-2 in LARC(PRIDE-02) | recruiting | Phase 2 | 122 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT07648589 | Glucose Homeostasis and Shared Genetic Factors in Colorectal Cancer(BRIDGE-CRCDM) | not yet recruiting | — | 200 | Chang Gung Memorial HospitalOTHER | 0 | Jun 15, 2026 | clinicaltrials |
| NCT07649057 | A Study of a Urine Test to Detect Colorectal Cancer | recruiting | — | 210 | Memorial Sloan Kettering Cancer CenterOTHER | 4 | Jun 15, 2026 | clinicaltrials |
| NCT04560712 | Acupuncture for the Management of Postoperative Pain in Patients With Pancreatic or Colorectal Cancer Undergoing Surgery | active not recruiting | N/A | 70 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT04616183 | LY3214996 and Cetuximab Alone or in Combination With Abemaciclib for the Treatment of Unresectable or Metastatic Colorectal Cancer | active not recruiting | Phase 1 / Phase 2 | 46 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT04729322 | Fecal Microbiota Transplant and Re-introduction of Anti-PD-1 Therapy (Pembrolizumab or Nivolumab) for the Treatment of Metastatic Colorectal Cancer in Anti-PD-1 Non-responders | active not recruiting | Phase 2 | 15 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT05239546 | Single Arm Study of Neoadjuvant Dostarlimab in Stage II and III Deficient Mismatch Repair Colon Cancers(NAIO) | recruiting | Phase 2 | 25 | University of IowaOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT05384444 | Effect of FMD on Colorectal Cancer Patients(FCRC22) | active not recruiting | N/A | 602 | Fudan UniversityOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT06051695 | A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression(EVEREST-2) | recruiting | Phase 1 / Phase 2 | 474 | A2 Biotherapeutics Inc.INDUSTRY | 1 | Jun 12, 2026 | clinicaltrials |
| NCT06756035 | CT-95 in Advanced Cancers Associated With Mesothelin Expression | recruiting | Phase 1 | 70 | Context Therapeutics Inc.INDUSTRY | 1 | Jun 12, 2026 | clinicaltrials |
| NCT07011576 | A Study of Fruquintinib Plus FOLFIRI as Second-Line Treatment for Participants With Metastatic Colorectal Cancer (FRUITFUL)(FRUITFUL) | recruiting | Phase 2 | 60 | SCRI Development Innovations, LLCOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT07612007 | HRX215, A First Generation MKK4 Inhibitor Drug, for the Treatment of Patients With Colorectal Liver Metastasis After Undergoing a Portal Vein Embolization | not yet recruiting | Phase 2 | 80 | Mayo ClinicOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT07638956 | ICG in Colon Cancer(ICG) | not yet recruiting | N/A | 25 | Tanta UniversityOTHER | 0 | Jun 12, 2026 | clinicaltrials |
| NCT07644286 | A Phase II Study of Pirfenidone Plus PD-1 Inhibitor With or Without Hypofractionated Radiotherapy for Refractory pMMR/MSS Colorectal Cancer | recruiting | Phase 2 | 48 | Tao ZhangOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT07645118 | Brachytherapy Followed by Nivolumab Prior to Surgery in Rectal Cancer(IMPERIA) | not yet recruiting | Phase 2 | 10 | Dr. Te VuongOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT07646106 | THE-0504 in Patients With Solid Tumors | recruiting | Phase 1 | 30 | Thena Biotech S.r.l.INDUSTRY | 1 | Jun 12, 2026 | clinicaltrials |
| NCT04017650 | Encorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal Cancer | active not recruiting | Phase 1 / Phase 2 | 38 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 11, 2026 | clinicaltrials |
| NCT04771520 | Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors | recruiting | Phase 2 | 50 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 11, 2026 | clinicaltrials |
| NCT05283330 | Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors | recruiting | Phase 1 | 48 | Orano Med Theranostics, SASINDUSTRY | 1 | Jun 11, 2026 | clinicaltrials |
| NCT06789172 | A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors(INVOKE) | recruiting | Phase 1 | 146 | EpkinINDUSTRY | 3 | Jun 11, 2026 | clinicaltrials |
| NCT07318389 | ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal Cancer | not yet recruiting | Early Phase 1 | 100 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 11, 2026 | clinicaltrials |
| NCT04587128 | Early-Line Anti-EGFR Therapy to Facilitate Retreatment for Select Patients With mCRC | active not recruiting | Phase 2 | 34 | University of Wisconsin, MadisonOTHER | 1 | Jun 10, 2026 | clinicaltrials |
| NCT04804956 | Mesorectal Microbiome and Metabolome as a Prognostic Factor in Patients With Rectal Cancer(BIORECTUM) | recruiting | — | 100 | University Hospital of Girona Dr. Josep TruetaNETWORK | 1 | Jun 10, 2026 | clinicaltrials |
| NCT05403177 | Marathon of Hope Cancer Centres Network Study for Ontario (MOHCCN-O)(MOHCCN-O) | recruiting | — | 500 | University Health Network, TorontoOTHER | 1 | Jun 10, 2026 | clinicaltrials |
| NCT06835569 | A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations | recruiting | Phase 1 | 448 | Alterome Therapeutics, Inc.INDUSTRY | 1 | Jun 10, 2026 | clinicaltrials |
| NCT03748485 | Adjuvant Chemotherapy in Clinical Local Advanced CRC Following Preoperational Therapies and pT0-3N0M0 Diagnosis(CANWATCH) | recruiting | N/A | 650 | Sixth Affiliated Hospital, Sun Yat-sen UniversityOTHER | 1 | Jun 9, 2026 | clinicaltrials |
| NCT05319314 | LYL273 for Patients With Relapsed or Refractory mCRC(CARABiNER) | recruiting | Phase 1 / Phase 2 | 155 | Lyell Immunopharma, Inc.INDUSTRY | 1 | Jun 9, 2026 | clinicaltrials |
| NCT06446557 | De-scalation or swItch of Treatment According to Circulating tuMOr DNA Variation After 2 Cycles of Doublet Chemotherapy Plus Targeted Agent in Metastatic Unresectable Colorectal Cancer(DIAMOND) | not yet recruiting | Phase 3 | 408 | University Hospital, RouenOTHER | 1 | Jun 9, 2026 | clinicaltrials |
| NCT07132970 | Leakage Rate of Ileo-COlic Sutured Anastomosis After Right Hemicolectomy(LICOSARH) | recruiting | — | 249 | Aesculap AGINDUSTRY | 1 | Jun 9, 2026 | clinicaltrials |
| NCT07188025 | ctDNA-Based Adjuvant Chemotherapy for High-Risk Rectal Cancer(REACT) | recruiting | Phase 3 | 103 | Erasmus Medical CenterOTHER | 1 | Jun 9, 2026 | clinicaltrials |
| NCT07306390 | Distribution and Analysis of Metastatic Lymph Nodes in Colorectal Cancer Patients (DIAMOND)(DIAMOND) | not yet recruiting | — | 1,200 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jun 9, 2026 | clinicaltrials |
| NCT07467434 | FOLFIRINOX Induction Chemotherapy for Synchronous Liver Metastases(SYNCHRONOX) | recruiting | — | 550 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Jun 9, 2026 | clinicaltrials |
| NCT03947385 | Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions | recruiting | Phase 1 / Phase 2 | 336 | IDEAYA BiosciencesINDUSTRY | 3 | Jun 8, 2026 | clinicaltrials |
| NCT05245786 | An Investigational Scan (64Cu-Labeled M5A Antibody) in Combination With SOC Chemotherapy and Radiotherapy in Locally Advanced Rectal Cancer | active not recruiting | Early Phase 1 | 14 | City of Hope Medical CenterOTHER | 1 | Jun 8, 2026 | clinicaltrials |
Data updated 24 days agoSource updated Jun 17, 2026source: clinicaltrials